BioMérieux and Diasorin, changes affect 2025 results

According to market indications, Diasorin would have been among the possible candidates, together with Hera, to exit the Ftse Mib index with the revision that will be active from next 22 December. But (fortunately for the Vercelli-based company and the Bologna-based utility) this will not be the case, because with the entry of Fincantieri it will instead exit the Interpump Group index.

However, the diagnostics sector, of which Diasorin is one of the main European representatives together with the transalpine BioMérieux, is going through a difficult period, partly due to the performance of the US market (impacted by tariffs) and its currency, as well as the ongoing contraction in the Chinese market. BioMérieux closed the first nine months of 2025 with revenues up 4.2% to EUR 2,991.9 million (+7.3% at constant exchange rates and perimeter); as usual, it did not provide data on profit margins, but in the first half of the year, turnover rose 7.5% to EUR 2.043.8 million (+9.5% at constant exchange rates and perimeter), ebit fell 27.4% to €209 million (+21.5% to €372 million but before non-recurring expenses) and net profit fell 25.2% to €161 million. Diasorin, as at 30/9/2025, saw revenues rise 3% to €900m (+5% at constant exchange rates), and excluding ex-Covid revenues the increase would have been 4% to €890m (+6% at constant exchange rates).

Ebitda and ebit were stable at EUR 291m and EUR 194m respectively (on an adjusted basis, +3% to EUR 302m for ebitda and +3% to EUR 233m for ebit), while net profit fell 3% to EUR 137m (-1% to EUR 174m on an adjusted basis). For the full year 2025, BioMérieux revised its guidance on revenue growth at constant exchange rates downwards (between 5.5% and 6.5%, previously between 6% and 7.5%), due to the lower pathogenicity in the respiratory segment compared to the first nine months of 2024, while an increase of between 12% and 18% in ebit before non-recurring expenses was confirmed, with a negative exchange rate effect estimated at around €30m (previously around €25m).

Diasorin has also revised downwards its estimates for revenue growth ex Covid 2025, which is expected to rise by 5% (+4% considering 10 million ex Covid sales), whereas previously the indication was +8% (+7% considering 20 million ex Covid sales). The adjusted ebitda margin is expected to be around 33% (previously around 34%).

The two groups are constantly pursuing research activities and launching new diagnostic tests, which for the French group are also aimed at the veterinary (equine) segment and the detection of pathogens in the service of food safety.